Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Philip D Bardwell

Chung-Ming Hsieh

Tariq Ghayur

Bernhard K Mueller

Yuliya Kutskova

John Memmott

Lili Huang

Martin Schmidt

Mary Leddy

Eve H Barlow

Provided herein are anti-Repulsive Guidance Molecule a (RGMa) antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Antibodies against the RGM a protein and uses thereof

Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Antibodies that bind to repulsive guidance molecule A (RGMA)

Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

Antibodies against the RGM A protein and uses thereof

Growing community of inventors

Boston, MA, United States of America

Philip D Bardwell